Analyzing Ocugen (NASDAQ:OCGN) and Lexeo Therapeutics (NASDAQ:LXEO)

Ocugen (NASDAQ:OCGN) and Lexeo Therapeutics (NASDAQ:LXEO) are both small-cap medical companies, but which is the better investment? We will compare the two companies based on the strength of their profitability, institutional ownership, analyst recommendations, dividends, risk, earnings and valuation.

Profitability

This table compares Ocugen and Lexeo Therapeutics’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Ocugen	-532.51%	-154.75%	-90.79%
Lexeo Therapeutics	N/A	-57.66%	-48.18%

Earnings and Valuation

This table compares Ocugen and Lexeo Therapeutics”s revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Ocugen	$4.06 million	52.42	-$63.08 million	($0.19)	-3.83
Lexeo Therapeutics	$650,000.00	182.33	-$66.39 million	($3.08)	-1.16

Ocugen has higher revenue and earnings than Lexeo Therapeutics. Ocugen is trading at a lower price-to-earnings ratio than Lexeo Therapeutics, indicating that it is currently the more affordable of the two stocks.

Volatility & Risk

Ocugen has a beta of 3.78, indicating that its share price is 278% more volatile than the S&P 500. Comparatively, Lexeo Therapeutics has a beta of 1.52, indicating that its share price is 52% more volatile than the S&P 500.

Analyst Ratings

This is a summary of recent recommendations and price targets for Ocugen and Lexeo Therapeutics, as reported by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Ocugen	0	0	3	0	3.00
Lexeo Therapeutics	0	0	5	1	3.17

Ocugen presently has a consensus price target of $6.33, suggesting a potential upside of 770.08%. Lexeo Therapeutics has a consensus price target of $22.20, suggesting a potential upside of 521.85%. Given Ocugen’s higher possible upside, research analysts plainly believe Ocugen is more favorable than Lexeo Therapeutics.

Insider & Institutional Ownership

10.3% of Ocugen shares are held by institutional investors. Comparatively, 60.7% of Lexeo Therapeutics shares are held by institutional investors. 4.3% of Ocugen shares are held by insiders. Comparatively, 4.5% of Lexeo Therapeutics shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

Summary

Lexeo Therapeutics beats Ocugen on 10 of the 15 factors compared between the two stocks.

About Ocugen

Ocugen, Inc., a clinical-stage biopharmaceutical company, focuses on discovering, developing, and commercializing novel gene and cell therapies and vaccines that improve patients’ health. The company’s pipeline product includes OCU400, a novel gene therapy product candidate restoring retinal integrity and function across a range of genetically diverse inherited retinal diseases, currently under Phase 3 trials for the treatment of retinitis pigmentosa and Phase 1/2 trials for the treatment of leber congenital amaurosis; OCU410, a gene therapy under phase 1/2 for the treatment of dry age-related macular degeneration (AMD); and OCU410ST, a gene therapy under phase 1/2 for the treatment of Stargardt disease. It is also involved in the development of OCU200, a novel fusion protein that is in preclinical development stage for the treatment of diabetic macular edema, diabetic retinopathy, and wet age-related macular degeneration; and NeoCart, an autologous chondrocyte-derived neocartilage, currently under Phase 3 studies indicated for the repair of knee cartilage injuries in adult. In addition, the company is developing OCU500, a COVID-19 vaccine; OCU510, a seasonal quadrivalent flu vaccine; and OCU520, a combination quadrivalent seasonal flu and COVID-19 vaccine. It has collaboration agreements with National Institute of Allergy and Infectious Diseases for early clinical studies for the OCU500 program; and a strategic partnership with CanSino Biologics Inc. for manufacturing its modifier gene therapy pipeline product candidates. The company was founded in 2013 and is headquartered in Malvern, Pennsylvania.

About Lexeo Therapeutics

Lexeo Therapeutics, Inc. operates as a clinical stage genetic medicine company that focuses on hereditary and acquired diseases. The company develops LX2006, which is an AAVrh10-based gene therapy candidate for the treatment of Friedreich's ataxia (FA) cardiomyopathy; LX2020, an AAVrh10-based gene therapy candidate for the treatment of plakophilin-2 arrhythmogenic cardiomyopathy; LX2021, a gene therapy candidate for the treatment of DSP cardiomyopathy associated with it; and LX2022, a gene therapy candidate for the treatment of hypertrophic cardiomyopathy, or HCM caused by TNNI3 gene. It also develops LX1001, an AAVrh10-based gene therapy candidate for the treatment of APOE4 homozygous; LX1020, a gene therapy candidate for the treatment of APOE4 homozygous; LX1021 for the treatment of APOE4 homozygotes; and LX1004 for the treatment of CLN2 Batten disease. The company was incorporated in 2017 and is based in New York, New York.